Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis

Clinical trial NCT07545213 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07545213
Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer EGFR Mutant Advanced Non-small Cell Lung Cancer

Start date: 2026-04-20
Primary completion: 2028-02-15
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.